Fig. 1: Clinical cohort overview.

Recurrent ovarian cancer patients were previously enrolled in a single-arm phase 2 clinical trial combining pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide therapy. Baseline (upon enrollment) and On-Treatment (Cycle 4, Day 1; C4D1) assessments, including tumor biopsies, blood samples, and stool collections, were obtained. The study diagram provides a thorough outline of the primary, secondary, and exploratory endpoints for the trial.